24小时热门版块排行榜

返回列表

本帖产生 1 个 LS-EPI ，点击这里进行查看

小木虫1985

银虫 (正式写手)

应助: 0 (幼儿园)
金币: 135
散金: 10
帖子: 368
在线: 124小时
虫号: 819879
注册: 2009-08-01
专业: 有机合成

[求助] 求US 2007099998专利的Chem. Abstr.号

怎么来搜索专利的CA号

回复此楼

» 猜你喜欢

请问哪里可以有青B申请的本子可以借鉴一下。已经有4人回复
真诚求助：手里的省社科项目结项要求主持人一篇中文核心，有什么渠道能发核心吗已经有6人回复
孩子确诊有中度注意力缺陷已经有14人回复
三甲基碘化亚砜的氧化反应已经有4人回复
请问下大家为什么这个铃木偶联几乎不反应呢已经有5人回复
请问有评职称，把科研教学业绩算分排序的高校吗已经有5人回复
2025冷门绝学什么时候出结果已经有3人回复
天津工业大学郑柳春团队欢迎化学化工、高分子化学或有机合成方向的博士生和硕士生加入已经有4人回复
康复大学泰山学者周祺惠团队招收博士研究生已经有6人回复
AI论文写作工具：是科研加速器还是学术作弊器？已经有3人回复

1楼2012-04-16 14:30:55

已阅回复此楼关注TA 给TA发消息送TA红花 TA的回帖

baiyuefei

版主 (文学泰斗)

风雪

LS-EPI: 1647
应助: 4642 (副教授)
贵宾: 46.969
金币: 657566
散金: 11616
红花: 995
沙发: 81
帖子: 69374
在线: 13265.6小时
虫号: 676696
注册: 2008-12-18
性别: GG
专业: 合成药物化学
管辖: 有机交流

【答案】应助回帖

去CA检索即可
结果如下
Bibliographic Information

Processes for preparing cinacalcet hydrochloride crystal form I.    Lifshitz-Liron, Revital; Avhar-Maydan, Sharon.  (Teva Pharmaceutical Industries Ltd., Israel; Teva Pharmaceuticals USA, Inc.). PCT Int. Appl.  (2006),    25pp.  CODEN: PIXXD2  WO  2006127933  A1  20061130  Designated States W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA.  Designated States RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IS, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, ML, MR, NE, SN, TD, TG.  Patent  written in English. Application: WO  2006-US20304  20060523.  Priority: US  2005-684152P  20050523; US  2005-696981P  20050705; US  2005-697111P  20050706; US  2005-698613P  20050711; US  2005-701232P  20050720; US  2005-702918P  20050726; US  2005-706910P  20050809; US  2005-730050P  20051024; US  2005-732083P  20051031; US  2005-733008P  20051102; US  2005-734669P  20051107; US  2005-735126P  20051108; US  2005-738827P  20051121; US  2005-741787P  20051201; US  2005-750910P  20051215; US  2006-794804P  20060424; WO  2006-US20304  20060523; EP  2006-771214  20060523; JP  2007-522852  20060523.  CAN 146:13204 AN 2006:1251817 CAPLUS

Patent Family Information

Patent No. Kind Date Application No. Date
WO 2006127933 A1 20061130 WO 2006-US20304 20060523
W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
CA 2606099 A1 20061130 CA 2006-2606099 20060523
US 20070060645 A1 20070315 US 2006-440246 20060523
US 7294735 B2 20071113
US 20070099998 A1 20070503 US 2006-439570 20060523
US 7247751 B2 20070724
BR 2006005859 A 20071218 BR 2006-5859 20060523
EP 1883618 A1 20080206 EP 2006-771215 20060523
EP 1883618 B1 20091014
R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
JP 2008507566 T 20080313 JP 2007-522852 20060523
JP 4638491 B2 20110223
EP 1975150 A1 20081001 EP 2008-12814 20060523
R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR
AT 445587 T 20091015 AT 2006-771215 20060523
ES 2334260 T3 20100308 ES 2006-771215 20060523
MX 2007000983 A 20070416 MX 2007-983 20070123
KR 2007083471 A 20070824 KR 2007-7001966 20070126
IN 2007DN08108 A 20080704 IN 2007-DN8108 20071019
CN 101180261 A 20080514 CN 2006-80017939 20071123
JP 2010280715 A 20101216 JP 2010-197123 20100902

Priority Application
US 2005-684152P P 20050523
US 2005-696981P P 20050705
US 2005-697111P P 20050706
US 2005-698613P P 20050711
US 2005-701232P P 20050720
US 2005-702918P P 20050726
US 2005-706910P P 20050809
US 2005-730050P P 20051024
US 2005-732083P P 20051031
US 2005-733008P P 20051102
US 2005-734669P P 20051107
US 2005-735126P P 20051108
US 2005-738827P P 20051121
US 2005-741787P P 20051201
US 2005-750910P P 20051215
US 2006-794804P P 20060424
WO 2006-US20304 W 20060523
EP 2006-771214 A3 20060523
JP 2007-522852 A3 20060523

Abstract

The invention provides processes for the prepn. of cinacalcet-HCl cryst. Form I.  Cinacalcet was dissolved in DMF and treated with 1N HCl to give the cryst. form I of the hydrochloride.

Indexing -- Section 63-6  (Pharmaceuticals)

Alcohols, uses
Role: NUU (Other use, unclassified); USES (Uses)
(C1-5; processes for prepg. cinacalcet hydrochloride crystal form I)

Alcohols, uses
Ethers, uses
Role: NUU (Other use, unclassified); USES (Uses)
(C2-5; processes for prepg. cinacalcet hydrochloride crystal form I)

Aromatic hydrocarbons, uses
Hydrocarbons, uses
Ketones, uses
Role: NUU (Other use, unclassified); USES (Uses)
(C3-6; processes for prepg. cinacalcet hydrochloride crystal form I)

Hydrocarbons, uses
Role: NUU (Other use, unclassified); USES (Uses)
(C5-8; processes for prepg. cinacalcet hydrochloride crystal form I)

Crystal structure
(of cinacalcet hydrochloride forms)

Antisolvents
Crystal morphology
Crystal polymorphism
(processes for prepg. cinacalcet hydrochloride crystal form I)

Esters, uses
Role: NUU (Other use, unclassified); USES (Uses)
(processes for prepg. cinacalcet hydrochloride crystal form I)

60-29-7, Diethyl ether, uses
64-17-5, Ethyl alcohol, uses
67-56-1, Methanol, uses
67-63-0, IPA, uses
67-64-1, Acetone, uses
67-68-5, Dimethyl sulfoxide, uses
68-12-2, Dimethylformamide, uses
75-05-8, Acetonitrile, uses
108-88-3, Toluene, uses
109-66-0, Pentane, uses
110-19-0, Isobutyl acetate
110-54-3, Hexane, uses
110-82-7, Cyclohexane, uses
127-19-5, DMAc
142-82-5, Heptane, uses
872-50-4, N-Methylpyrrolidone, uses
1634-04-4, MTBE
Role: NUU (Other use, unclassified); USES (Uses)
(processes for prepg. cinacalcet hydrochloride crystal form I)

364782-34-3P, Cinacalcet hydrochloride
Role: PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(processes for prepg. cinacalcet hydrochloride crystal form I)

226256-56-0, Cinacalcet
Role: RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); USES (Uses); RACT (Reactant or reagent)
(processes for prepg. cinacalcet hydrochloride crystal form I)

Supplementary Terms

cinacalcet hydrochloride crystal form prepn

Citations

Iqbal, J; IDRUGS 2003, 6(6), 587
Anon; SUMMARY BASIS OF APPROVAL OF NEW DRUG APPLICATION #21-688 2004